Induction of the DNA damage marker, γH2AX, indicates that a similar mechanism may operate in other p53-mutated human B-lymphoid cancers, such as the cell lines MEC2 (CLL) and U266 (multiple myeloma). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.